Related Experiment Video
Updated: Jul 28, 2026
Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
Published on: May 1, 2015
OK-432 therapy for lymphangiomas
Objective:
To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
Design:
Nonrandomized trial; follow-up, 4 to 29 months.
Setting:
Academic tertiary referral medical center.
Patients:
Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.
Intervention:
Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.
Outcome Measures:
Clinical and radiographic comparisons before and after therapy.
Results:
Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.
Conclusion:
OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.
